arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Compass Therapeutics, Inc.

CMPX

$2.15 ▲ +0.16 (+7.79%) at close

9 Visible periods

25 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Compass Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $339.0M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -29.2% ↗

FCF / Share $-0.31 ↗

Trailing P/E —

Price / Book 2.0x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

9-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

↓ -100.0% —

Net Income Profit after all expenses

$-66.49M

↓ -34.7% —

FCF / Share Free cash flow per share

$-0.31

↑ +4.6% —

Long-Term Debt Long-term obligations

$1.87M

↓ -79.9% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Mar 31, 2019 10-K ↗	FY 2017 Mar 31, 2018 10-K ↗
EPS Growth YoY (%)	-16.7% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-9.1% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	10.8% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	71.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	-34.7% Weak ↓ Weak Declining Year-over-year change in net income	-16.2% Weak ↑ Weak Improving Year-over-year change in net income	-8.3% Weak ↑ Weak Improving Year-over-year change in net income	52.3% Excellent ↑ Excellent Improving Year-over-year change in net income	-178.6% Weak ↑ Weak Improving Year-over-year change in net income	15.1% Good Good Year-over-year change in net income	-96312.0% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	4.6% Caution ↑ Caution Improving Year-over-year change in free cash flow	-2.1% Weak ↓ Weak Declining Year-over-year change in free cash flow	2.0% Caution Caution Year-over-year change in free cash flow	3.3% Caution Caution Year-over-year change in free cash flow	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Mar 31, 2019 10-K ↗	FY 2017 Mar 31, 2018 10-K ↗
Effective Tax Rate (%) (%)	—	—	—	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.3% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
FCF / Net Income (x)	0.74x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.26x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Mar 31, 2019 10-K ↗	FY 2017 Mar 31, 2018 10-K ↗
Return on Invested Capital (%)	-29.2% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-35.7% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-26.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-22.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-58.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-66.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	31.2% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	36.7% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-33.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-40.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-32.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-20.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-53.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-53.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-112.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	-673.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-33.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-325%)	-39.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-363%)	-28.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-291%)	-21.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-244%)	-58.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-491%)	-73.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-592%)	29.3% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+95%)	51.1% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+240%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Mar 31, 2019 10-K ↗	FY 2017 Mar 31, 2018 10-K ↗
Debt to Equity (x)	—	—	—	—	—	0.05x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-92%)	-0.08x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-113%)	—	—
Interest Coverage (x)	—	—	—	—	-221.30x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-30.63x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-27.73x Weak Weak Operating income divided by interest expense Optimal: > 5x	-9.99x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-30.64M	$-43.48M	$-24.23M	$-34.95M	$-144.51M	$-45.21M	$-16.01M	$-4.87K	—
Debt / EBITDA (x)	—	—	—	—	—	-0.07x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.29x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Mar 31, 2019 10-K ↗	FY 2017 Mar 31, 2018 10-K ↗
Revenue per Share (USD)	$0.00	$0.01	$0.00	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-0.42	$-0.36	$-0.33	$-0.37	$-1.31	—	—	—	—
Free Cash Flow per Share (USD)	$-0.31	$-0.33	$-0.32	$-0.33	$-0.34	—	—	—	—
Book Value per Share (USD)	$1.10	$0.91	$1.16	$1.44	$1.39	$0.78	$-16.86	$-0.01	$-0.01
Tangible Book Value per Share (USD)	$1.10	$0.91	$1.16	$1.44	$1.39	$0.78	$-16.86	$-0.01	$-0.01
Basic Weighted Avg Shares (shares)	157.69M	137.38M	127.03M	105.19M	62.87M	—	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Mar 31, 2019 10-K ↗	FY 2017 Mar 31, 2018 10-K ↗
Working Capital (USD)	$195.85M	$123.88M	$146.08M	$178.62M	$136.47M	$40.10M	$16.42M	$-70.59K	$-34.55K
LT Debt (USD)	—	—	—	—	—	$1.87M	$9.29M	—	—
Total Equity (USD)	$196.79M	$125.23M	$148.54M	$181.64M	$140.08M	$39.95M	$-118.60M	$-70.59K	$-34.55K

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Mar 31, 2019 10-K ↗	FY 2017 Mar 31, 2018 10-K ↗
Sales/Revenue/Turnover (USD)	$0.00	$850.00K	$0.00	—	—	—	—	—	—
Depreciation Expense (USD)	$300.00K	$600.00K	$700.00K	$800.00K	$600.00K	$2.40M	$2.10M	—	—
Net Income, GAAP (USD)	$-66.49M	$-49.38M	$-42.49M	$-39.23M	$-82.18M	$-29.50M	$-34.74M	$-36.04K	—
Operating Cash Flow (USD)	$-49.14M	$-44.85M	$-40.62M	$-34.12M	$-19.67M	$-26.80M	$-31.74M	$-32.76K	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 34 quarters

Compass Therapeutics, Inc.

Analytical Summary

9-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CMPX with peers